rheumatoid arthritis

AbbVie keen on JAK inhibitor despite safety concerns
AbbVie keen on JAK inhibitor despite safety concerns
BioPharma Dive
AbbVie
JAK inhibitors
Upadacitinib
ABT-494
rheumatoid arthritis
Flag link:
AbbVie reports two patient deaths in rheumatoid arthritis study
AbbVie reports two patient deaths in rheumatoid arthritis study
Yahoo/Reuters
AbbVie
clinical trials
rheumatoid arthritis
Upadacitinib
ABT-494
Flag link:
Eli Lilly Preps Rejected Rheumatoid Arthritis Drug for Resubmission
Eli Lilly Preps Rejected Rheumatoid Arthritis Drug for Resubmission
Xconomy
Eli Lilly
rheumatoid arthritis
FDA
baricitinib
Flag link:
J&J set back by negative panel vote for sirukumab
J&J set back by negative panel vote for sirukumab
BioPharma Dive
JNJ
FDA
sirukumab
advisory panels
rheumatoid arthritis
Flag link:
J&J arthritis drug sirukumab raises safety concerns -FDA staff
J&J arthritis drug sirukumab raises safety concerns -FDA staff
Yahoo/Reuters
JNJ
FDA
sirukumab
rheumatoid arthritis
Flag link:
Torpedoed by blood clots, Eli Lilly says a baricitinib comeback in rheumatoid arthritis could take years
Torpedoed by blood clots, Eli Lilly says a baricitinib comeback in rheumatoid arthritis could take years
Endpoints
baricitinib
Eli Lilly
blood clots
rheumatoid arthritis
Flag link:
Novartis stocks drug cabinet with "Big-3" arthritis blockbusters
Novartis stocks drug cabinet with "Big-3" arthritis blockbusters
Yahoo/Reuters
Novartis
rheumatoid arthritis
generics
Sandoz
Amgen
Enbrel
JNJ
Remicade
AbbVie
Humira
Flag link:
In latest setback, another Coherus partner bails out on Amgen biosimilar deal
In latest setback, another Coherus partner bails out on Amgen biosimilar deal
Endpoints
Coherus
Amgen
biosimilars
Daiichi Sankyo
CHS-0214
rheumatoid arthritis
Enbrel
Flag link:
Lilly’s Olumiant, spurned by FDA, gets nod from NICE
Lilly’s Olumiant, spurned by FDA, gets nod from NICE
Fierce Pharma
FDA
NICE
Europe
Eli Lilly
olumiant
rheumatoid arthritis
Humira
Flag link:
Pfizer’s Xeljanz: Results from the ORAL Strategy
Pfizer’s Xeljanz: Results from the ORAL Strategy
Market Realist
Pfizer
Xeljanz
rheumatoid arthritis
Flag link:
J&J unveils new obesity, arthritis collaborations, shares its molecule library
J&J unveils new obesity, arthritis collaborations, shares its molecule library
Fierce Biotech
JNJ
obesity
rheumatoid arthritis
molecules
molecule library
drug development
Flag link:
First PhIII trial of AbbVie’s upadacitinib a success
First PhIII trial of AbbVie’s upadacitinib a success
Pharma Times
AbbVie
Upadacitinib
clinical trials
rheumatoid arthritis
Flag link:
Abbvie Vaults First Pivotal Hurdle With Oral RA Candidate
Abbvie Vaults First Pivotal Hurdle With Oral RA Candidate
Seeking Alpha
AbbVie
rheumatoid arthritis
Upadacitinib
Flag link:
Sanofi, Regeneron set Kevzara up for tough rheumatoid arthritis turf battle with $39K list price
Sanofi, Regeneron set Kevzara up for tough rheumatoid arthritis turf battle with $39K list price
Fierce Pharma
Sanofi
Regeneron
Kevzara
rheumatoid arthritis
Flag link:
EMA panel recommends nod for Sanofi, Regeneron's arthritis drug
EMA panel recommends nod for Sanofi, Regeneron's arthritis drug
Yahoo/Reuters
Europe
EMA
Sanofi
Regeneron
rheumatoid arthritis
Kevzara
Sarilumab
Flag link:
Lilly and Incyte's Loss Is AbbVie and Regeneron's Gain
Lilly and Incyte's Loss Is AbbVie and Regeneron's Gain
Motley Fool
Eli Lilly
Inctye
AbbVie
Regeneron
rheumatoid arthritis
FDA
baricitinib
Humira
Flag link:
The FDA shot down a new rheumatoid arthritis drug — and the companies that make the drug are tumbling
The FDA shot down a new rheumatoid arthritis drug — and the companies that make the drug are tumbling
Yahoo/Business Insider
FDA
rheumatoid arthritis
Eli Lilly
Incyte
baricitinib
Flag link:
Eli Lilly and Incyte say FDA failed to approve their rheumatoid arthritis drug
Eli Lilly and Incyte say FDA failed to approve their rheumatoid arthritis drug
Marketwatch
Eli Lilly
Incyte
FDA
rheumatoid arthritis
baricitinib
Flag link:
$5B in Humira sales at stake with Amgen EU approval
$5B in Humira sales at stake with Amgen EU approval
BioPharma Dive
Humira
Amgen
Europe
rheumatoid arthritis
Amgevita
biosimiliars
Flag link:
Pfizer Announces Approval By The China Food And Drug Administration Of XELJANZ®, The First Oral JAK Inhibitor For Adult Patients With Moderately To Severely Active Rheumatoid Arthritis
Pfizer Announces Approval By The China Food And Drug Administration Of XELJANZ®, The First Oral JAK Inhibitor For Adult Patients With Moderately To Severely Active Rheumatoid Arthritis
Yahoo
Pfizer
China
Xeljanz
rheumatoid arthritis
Flag link: